ArticleJournal of neuro-oncology2026
Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo test, under a pre-planned clinical framework, whether simple multiparametric MRI biomarkers show candidate associations with selected molecular alterations in primary central nervous system lymphoma (PCNSL), with a focus on non-invasive enrichment for CD79B status and the MCD-like phenotype of potential relevance to Bruton tyrosine kinase (BTK) inhibitor stratification.
methodsThe public UCSF-PCNSL dataset (146 patients; 63 with UCSF500 cancer gene panel) was analyzed. Four clinically motivated MRI biomarker-to-genotype pairings (CD79B, MCD-like, TP53, and CDKN2A/B) were defined in advance of any statistical testing. Effect sizes were reported as Cliff's delta with 95% bootstrap confidence intervals, and one-sided p-values were adjusted for multiple testing across the four hypotheses at a false-positive threshold of 0.05. Reproducibility was examined by refitting each test after removing one scanner batch at a time (six batches total), and by benchmarking the habitat biomarkers against simple volumetric predictors using cross-validated AUROC.
resultsThe principal hypothesis (H1) showed a higher enhancing-core (h1) fraction in CD79B-mutant patients (Cliff's delta + 0.34, 95% CI + 0.04 to + 0.63; rank AUC 0.67; p = 0.015; direction preserved in 6/6 scanner batches). H3 was directionally consistent: higher FLAIR/T1c ratio in TP53-mutant patients (delta + 0.31; p = 0.049). MCD-like and CDKN2A/B hypotheses were not supported. After correction for multiple testing, no test reached the 0.05 threshold.
conclusionIn this exploratory analysis, enhancing-core fraction on routine MRI emerged as the leading candidate signal for CD79B status in PCNSL, with FLAIR/T1c ratio as a directionally consistent secondary signal for TP53. After correction for multiple testing across the four pre-specified comparisons no test reached the 0.05 threshold; the findings should therefore be considered hypothesis-generating. External multicenter replication, ideally with full LymphGen classification, is required before these biomarkers can be considered for clinical use.
Indexed as
Identifiers
42213292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.